Explainers
Cancer topic explainers
Short explanations for common questions. Educational, not news, and not yet clinician reviewed.
EGFR after osimertinib
Open Lung Cancer →My treatment stopped working. What does the next step depend on?
- EGFR after osimertinibDraft, not yet medically reviewed
EGFR after osimertinib: fourth-generation trials are starting to report early results
No fourth-generation EGFR targeted therapy has been approved anywhere. Candidates such as JIN-A02 are being tested in phase 1/2 for patients who progress after osimertinib, including cases with C797S resistance. The published early results are small and are not proof of efficacy.Updated 2026-09-15 · 6 min readRead → - EGFR after osimertinibDraft, not yet medically reviewed
Why treatment guidelines differ between countries
Guidelines differ because they consider available evidence, medicine availability, regulation, and local service context. Differences may emphasize different options and do not automatically mean one guideline is wrong.Updated 2026-09-11 · 5 min readRead → - EGFR after osimertinibDraft, not yet medically reviewed
What recruiting status means in a clinical trial registry
Recruiting status means a study is listed as seeking participants. It does not mean a site is active, that international patients are accepted, or that a person meets protocol criteria.Updated 2026-09-11 · 5 min readRead → - EGFR after osimertinibDraft, not yet medically reviewed
Why a medicine approved abroad is not automatically available in Indonesia
Regulatory approval applies to the jurisdiction that issued it. A medicine approved in one country may not have marketing authorization, availability, or payment coverage in Indonesia.Updated 2026-09-11 · 5 min readRead → - EGFR after osimertinibDraft, not yet medically reviewed
What biomarker results do and do not say
A biomarker result shows a tumor feature that can influence which treatment categories are discussed. It does not establish the final diagnosis, choose a regimen, or guarantee treatment success.Updated 2026-09-11 · 6 min readRead → - EGFR after osimertinibDraft, not yet medically reviewed
Why stage 4 is not one single disease
Stage 4 means cancer has spread beyond its original site, but it does not describe one uniform condition. Two people with stage 4 disease may differ by cancer type, spread pattern, molecular markers, and general condition.Updated 2026-09-11 · 5 min readRead →
CLDN18.2 in stomach cancer
Open Stomach Cancer →A CLDN18.2 result is positive. What does it mean and what is worth discussing with the medical team?
- CLDN18.2 in stomach cancerDraft, not yet medically reviewed
CLDN18.2: China approved zolbetuximab for first line care - what it means for Indonesian patients
China's regulator, NMPA, approved zolbetuximab in June 2025 as first-line treatment with chemotherapy for advanced CLDN18.2-positive, HER2-negative gastric or gastroesophageal-junction adenocarcinoma. The decision changes what may be worth discussing, but it does not automatically mean the medicine is available in Indonesia or at every hospital in China.Updated 2026-09-15 · 5 min readRead → - CLDN18.2 in stomach cancerDraft, not yet medically reviewed
What recruiting status means in a clinical trial registry
Recruiting status means a study is listed as seeking participants. It does not mean a site is active, that international patients are accepted, or that a person meets protocol criteria.Updated 2026-09-11 · 5 min readRead → - CLDN18.2 in stomach cancerDraft, not yet medically reviewed
What biomarker results do and do not say
A biomarker result shows a tumor feature that can influence which treatment categories are discussed. It does not establish the final diagnosis, choose a regimen, or guarantee treatment success.Updated 2026-09-11 · 6 min readRead →
7 explainers indexed on this page.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.